OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.

US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.

Sanofi and Gilead moved down in the rankings of Scrip's top 100 pharmaceutical companies, based on 2017 pharma sales, while Johnson & Johnson, GSK and AbbVie moved up. Shire joined the top 20 just as it is about to be consumed by Takeda.

Novo Nordisk' obesity pipeline consists of projects addressing both appetite reduction and energy expenditure, with GLP-1 semaglutide topping the list, its CSO says in an interview with Scrip.

It was inevitable that Brexit would be the key theme of an interview with Danish Medicines Agency head Thomas Senderovitz earlier this year. The senior European regulator oversees one of the agencies that has taken on new staff to help deal with the impact, in drug regulatory terms, of the vote by the UK in June 2016 to leave the European Union. Senderovitz also chairs the management group of the EU Heads of Medicines Agencies network.

The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.

Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition  heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.

In "very top-line" Phase IIb data, the magnitude of the treatment effect for valbenazine in children with Tourette syndrome was weaker than expected, and its loss from active development means there will be only a handful of candidates under evaluation for the disorder.

Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector.